Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials
click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate



Tuesday, January 13, 2015

Six-week Oral Drug Trial Produces High Hepatitis C Cure Rates

A recent clinical trial, published in The Lancet, involving a 6-week course of a combination of 3 direct-acting oral drugs was found to cure 38 of 40 individuals with hepatitis C virus infection (HCV).

The researchers had found that a 6-week course of therapy is actually half the length of time typically reported to achieve a similar, successful cure rate using only2 direct-acting oral HCV drugs.

For the clinical trial, the first group of 20 volunteers were administered a 6-week course of the newly licensed drug sofosbuvir (Sovaldi) coupled with 2 additional direct-acting oral therapies, ledipasvir and GS-9669 – an experimental drug. The second volunteer group also comprised of 20 individuals had received another 6-week course of sofosbuvir, ledipasvir, and a different experimental drug, GS-9451

. - See more at: http://www.hcplive.com/articles/Six-week-Oral-Drug-Trial-Produces-High-Hepatitis-C-Cure-Rates#sthash.eftwAdC7.dpuf

No comments:

Post a Comment